

Nippon India Consumption Fund

Thematic Fund

Details as on April 30, 2020

Type of Scheme

An Open Ended Equity Scheme following consumption theme

Current Investment Philosophy

The fund has a focused approach to investing in leaders or potential leaders that are likely to benefit directly or indirectly from domestic consumption led demand. It is well diversified across key segments like Consumer Non-Durables, Media & Entertainment, Automobile, Healthcare Services, Pharmaceuticals, etc., driven by relative attractiveness of Opportunities and Valuations. The fund has a flexi cap structure, allowing it to participate across market caps. Strong business model that allows for good ROE generation will be the primary basis for investment. Businesses with focus on sustainable profitable growth will be the core components of the investment universe.

Date of Allotment

September 30, 2004

Fund Manager

Sailesh Raj Bhan

Benchmark

Nifty India Consumption TRI

Fund size

Monthly Average: ₹ 71.81 Cr

Month End: ₹ 75.67 Cr

NAV as on April 30, 2020

Growth Plan	₹ 59.1970	Direct - Growth Plan	₹ 62.6315
Dividend Plan	₹ 15.4161	Direct - Dividend Plan	₹ 20.5988
Bonus Option	₹ 59.1970	Direct - Bonus Option	₹ 62.6315

Portfolio Turnover (Times) 0.78

Total Expense Ratio^

Regular/Other than Direct 2.70

Direct 2.00

Load structure

Entry Load: Nil

Exit Load: 10% of the units allotted shall be redeemed without any exit load, on or before completion of 12 months from the date of allotment of units.

Any redemption in excess of such limit in the first 12 months from the date of allotment shall be subject to the following exit load, Redemption of units would be done on First in First out Basis (FIFO):

• 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units. • Nil, thereafter, w.e.f. March 17, 2020

Special Feature: Nippon India Any Time Money Card

Please refer page no. 82 for explanation on symbol: ^ and @ wherever available

Portfolio as on April 30, 2020

Company/Issuer	% of Assets
Auto	
Maruti Suzuki India Limited*	5.67
Hero MotoCorp Limited*	5.15
Mahindra & Mahindra Limited*	3.88
Bajaj Auto Limited*	3.47
TVS Motor Company Limited	2.17
Eicher Motors Limited	1.94
Consumer Durables	
Dixon Technologies (India) Limited*	6.04
Titan Company Limited	3.20
Consumer Non Durables	
ITC Limited*	10.95
Asian Paints Limited*	6.97
Tata Consumer Products Limited*	4.65
United Spirits Limited*	3.55
Varun Beverages Limited	2.77
Dabur India Limited	2.63
Britannia Industries Limited	2.09
Bajaj Consumer Care Limited	1.44

Company/Issuer	% of Assets
Emami Limited	1.29
United Breweries Limited	1.24
Hotels, Resorts And Other Recreational Activities	
The Indian Hotels Company Limited	1.48
Media & Entertainment	
INOX Leisure Limited	1.96
Retailing	
Trent Limited	3.14
Aditya Birla Fashion and Retail Limited	2.29
Telecom - Services	
Bharti Airtel Limited*	10.94
Textile Products	
TCNS Clothing Co. Limited	1.04
Transportation	
InterGlobe Aviation Limited	3.16
Equity Less Than 1% of Corpus	1.38
Cash and Other Receivables	5.55
Grand Total	100.00

*Top 10 Holdings

For SIP performance refer page 61. For scheme performance refer page 63-70. For Fund manager wise scheme performance refer page 71-74.

Volatility Measures

Standard Deviation	5.76	Beta	0.91	Sharpe Ratio	-0.10
--------------------	------	------	------	--------------	-------

Note: The above measures have been calculated using monthly rolling returns for 36 months period with 4.41% risk free return (FBIL Overnight MIBOR as on 30/04/2020).

Dividend History

Record Date	Rate (₹/ Unit)	Cum Dividend NAV	Ex-Dividend NAV	Record Date	Rate (₹/ Unit)	Cum Dividend NAV	Ex-Dividend NAV
Dividend Plan				Direct - Dividend Plan			
24-Jan-20	1.33	19.9981	18.4981	24-Jan-20	1.33	26.1448	24.6448
18-Jan-19	1.55	19.4422	17.6922	18-Jan-19	1.55	24.7609	23.0109
19-Jan-18	2.50	24.4435	21.9435	19-Jan-18	2.50	30.1875	27.6875


Past performance may or may not be sustained in future. Pursuant to dividend payment, NAV falls to the extent of payout & statutory levy (if applicable). Face Value-₹10.

Product Label

This product is suitable for investors who are seeking*:

- Long term capital growth
- Investment in equity, equity related securities of companies that are likely to benefit directly or indirectly from domestic consumption led demand.

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.



Nippon India Pharma Fund

Sector Fund

Details as on April 30, 2020

Type of Scheme

An open ended equity scheme investing in pharma sector

Current Investment Philosophy

The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.

Date of Allotment

June 5, 2004

Fund Manager

Sailesh Raj Bhan

Benchmark

S&P BSE Healthcare TRI

Fund size

Monthly Average: ₹ 2,649.57 Cr

Month End: ₹ 2,850.69 Cr

NAV as on April 30, 2020

Growth Plan	₹ 179.6739	Direct - Growth Plan	₹ 190.8766
Dividend Plan	₹ 56.5264	Direct - Dividend Plan	₹ 71.7525
Bonus Option	₹ 179.6739	Direct - Bonus Option	₹ 190.8766

Portfolio Turnover (Times) 0.27

Total Expense Ratio^

Regular/Other than Direct 2.13

Direct 1.30

Load structure

Entry Load: Nil

Exit Load: 10% of the units allotted shall be redeemed without any exit load, on or before completion of 12 months from the date of allotment of units.

Any redemption in excess of such limit in the first 12 months from the date of allotment shall be subject to the following exit load, Redemption of units would be done on First in First out Basis (FIFO):

• 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units.

• Nil, thereafter, w.e.f. March 17, 2020

Special Feature: Nippon India Any Time Money Card

Please refer page no. 82 for explanation on symbol: ^ and @ wherever available

Portfolio as on April 30, 2020

Company/Issuer	% of Assets
Healthcare Services	
Fortis Healthcare Limited*	4.72
Thyrocare Technologies Limited*	4.53
Narayana Hrudayalaya Limited	2.78
Pharmaceuticals	
Aurobindo Pharma Limited*	10.98
Dr. Reddy's Laboratories Limited*	10.36
Sun Pharmaceutical Industries Limited*	10.27
Divi's Laboratories Limited*	9.00
Cipla Limited*	7.86
Lupin Limited*	7.33
Syngene International Limited*	4.86

Company/Issuer	% of Assets
Sanofi India Limited*	4.77
Abbott India Limited	4.36
Biocon Limited	4.36
Cadila Healthcare Limited	3.97
Alkem Laboratories Limited	3.57
Indoco Remedies Limited	2.50
Equity Less Than 1% of Corpus	0.26
Cash and Other Receivables	3.53
Grand Total	100.00

*Top 10 Holdings

For SIP performance refer page 61. For scheme performance refer page 63-70. For Fund manager wise scheme performance refer page 71-74.

Volatility Measures

Standard Deviation	5.97	Beta	0.83	Sharpe Ratio	0.11
--------------------	------	------	------	--------------	------

Note: The above measures have been calculated using monthly rolling returns for 36 months period with 4.41% risk free return (FBIL Overnight MIBOR as on 30/04/2020).

Dividend History

Record Date	Rate (₹/ Unit)	Cum Dividend NAV	Ex-Dividend NAV	Record Date	Rate (₹/ Unit)	Cum Dividend NAV	Ex-Dividend NAV
Dividend Plan				Direct - Dividend Plan			
28-Feb-20	3.98	52.8841	48.3841	28-Feb-20	3.98	65.8193	61.3193
01-Mar-19	4.43	56.5884	51.5884	01-Mar-19	4.43	68.7031	63.7031
01-Mar-18	6.00	58.6103	52.6103	01-Mar-18	6.00	69.2904	63.2904

Past performance may or may not be sustained in future. Pursuant to dividend payment, NAV falls to the extent of payout & statutory levy (if applicable). Face Value-₹10.

Product Label

This product is suitable for investors who are seeking*:

- Long term capital growth
- Investment in equity and equity related securities of pharma & other associated companies

*Investors should consult their financial advisors if in doubt about whether the product is suitable for them.

